A phase III randomised, double-blind parallel group extension study to investigate the safety and efficacy of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 mg or of linagliptin 2.5 mg + metformin 1000 mg versus monotherapy with metformin 1000 mg over 54 weeks in type 2 diabetic patients previously completing the double-blind part of study 1218.46 [EXTENSION OF 700039451]
Latest Information Update: 07 Oct 2021
At a glance
- Drugs Linagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim GmbH International; Boehringer Ingelheim Pharmaceuticals
- 11 Dec 2013 New source identified and integrated (ClinicalTrials.gov record; NCT00915772)
- 10 Apr 2013 New source identified and integrated (Clinical Trials Registry - India; CTRI2009-091-000950).
- 14 Feb 2013 New trial record